Practice patterns in the use of anti-tumor necrosis factor alpha agents in the management of Crohn's disease: A US national practice survey comparing experts and non-experts

Digestive Diseases and Sciences

Volumn 56, Issue 4, 2011, Pages 1160-1164

  Swaminath, Arun ^a   Lebwohl, Benjamin ^a   Capiak, Kristina M ^a   Present, Daniel H ^b  

^a NewYork Presbyterian Hospital   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Biologics; Continuous quality improvement; Crohn's disease; Inflammatory bowel disease; Survey; TNF alpha

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CYCLOSPORIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; CROHN DISEASE; CYTOPENIA; DRUG EFFICACY; DRUG USE; HEALTH CARE SURVEY; HISTOPLASMOSIS; HUMAN; INFUSION REACTION; LYMPHOMA; MEDICAL EXPERT; MULTIPLE SCLEROSIS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SKIN CANCER; TREATMENT CONTRAINDICATION; TUBERCULOSIS; UNITED STATES;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; CROHN DISEASE; GASTROINTESTINAL AGENTS; HEALTH CARE SURVEYS; HUMANS; METHOTREXATE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 79955623950     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-010-1530-9     Document Type: Article

References (15)

1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549. doi:S0140-6736(02)08512-4[pii]10.1016/S0140-6736(02)08512-4.
3. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333. doi:quiz591S0016-5085(05)02315-2[pii]10. 1053/j.gastro.2005.11.030.
4. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239. doi:gut.2006.106781[pii]10.1136/gut.2006.106781.
5. Sands BE, Blank MA, Patel K, et al. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004;2:912-920. doi:S1542356504004148[pii].
6. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357:228-238. doi:357/3/228[pii]10.1056/NEJMoa067594.
7. Schwartz DA. The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn's disease: an interview with David A Schwartz, 13 June 2007. Biologics. 2008;2:126-128.
8. Mushlin AI, Ghomrawi H. Health care reform and the need for comparative-effectiveness research. N Engl J Med. 2010;362:e6.
9. Donovan M, Lunney K, Carter-Pokras O, et al. Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists. Dig Dis Sci. 2007;52:1798-1805. (Pubitemid 47024654)
10. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med. 1995;332:292-297.
11. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
12. El Mourabet M, El-Hachem S, Harrison JR, et al. Anti-TNF antibody therapy for inflammatory bowel disease during pregnancy: a clinical review. Curr Drug Targets. 2010;11:234-241.
13. Mahadevan U, Kane S. Use of infliximab in pregnancy. Am J Gastroenterol. 2010;105:219. author reply 219-20.
14. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006;131:283-311. (Pubitemid 44015759)
15. Oussalah A, Roblin X, Laharie D, et al. Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey. Aliment Pharmacol Ther. 2009;30:854-863.